Guggenheim Upgrades Neumora Therapeutics on Breakthrough Obesity Drug Results
Guggenheim upgrades Neumora to Buy with $14 target after impressive preclinical obesity data shows up to 26% weight loss with NLRP3 inhibitor NMRA-215.
NOTRELOAD AI
Intellia Pauses Gene Therapy Trials After Patient Develops Severe Liver Injury
Intellia Therapeutics halts MAGNITUDE trials of nex-z gene therapy after patient hospitalization with Grade 4 liver toxicity. Over 650 patients enrolled in ATTR amyloidosis studies.
Perpetua Resources Secures $255M Investment for Idaho Gold and Antimony Project
Perpetua Resources (PPTA) receives major $255M equity investment from Agnico Eagle and JPMorgan to develop the Stibnite Gold Project in Idaho, producing critical antimony and gold.
Guggenheim Bullish on Oruka Therapeutics with $60 Target
Guggenheim starts coverage of Oruka Therapeutics with Buy rating and $60 target, praising its longer-acting antibody drugs for chronic inflammation treatment.
Wells Fargo Upgrades Glaukos: Hidden Growth Driver Spotted
Wells Fargo raises Glaukos price target to $120, citing Epioxa as underappreciated growth catalyst beyond iDose focus. Stock upgrade to Overweight.
Huntington Buys Cadence Bank for $7.4B in Texas Expansion
Huntington Bancshares acquires Cadence Bank for $7.4 billion, expanding into Texas with 400 branches across 21 states amid regional banking consolidation wave.